

参考文献

1. Institute of Medicine (US) Committee on Use of Dietary Reference Intakes in Nutrition Labeling (2003) Dietary Reference Intakes: Guiding Principles for Nutrition Labeling and Fortification. (栄養表示における食事摂取基準の使用に関する委員会(2003) 食事摂取基準: 栄養表示と栄養強化に関する指針) PMID: <https://pubmed.ncbi.nlm.nih.gov/24967483/>
2. Levy T (2023) <http://orthomolecular.org/resources/omns/v19n36.shtml>
3. Ferrier I (1985) Water intoxication in patients with psychiatric illness. (精神疾患患者における水中毒) British Medical Journal (Clinical Research Ed.) 291:1594-1596. PMID: <https://pubmed.ncbi.nlm.nih.gov/3935199/>
4. de Leon J, Verghese C, Tracy J et al. (1994) Polydipsia and water intoxication in psychiatric patients: a review of the epidemiological literature. (精神病患者における多飲症と水中毒: 疫学的文献のレビュー) Biological Psychiatry 35:408-419. PMID: <https://pubmed.ncbi.nlm.nih.gov/8018788/>
5. Siegel A (2015) Fatal water intoxication and cardiac arrest in runners during marathons: prevention and treatment based on validated clinical paradigms. (マラソン中のランナーにおける致死的な水中毒と心停止: 有効な臨床パラダイムに基づく予防と治療) The American Journal of Medicine 128:1070-1075. PMID: <https://pubmed.ncbi.nlm.nih.gov/25910792/>
6. Levy T (2002) Curing the Incurable: Vitamin C, Infectious Diseases, and Toxins (不治の病を治す: ビタミンCと感染症・毒素) Henderson, NV: MedFox Publishing
7. Levy T (2021) <http://orthomolecular.org/resources/omns/v17n28.shtml>
8. Levy T, Hunninghake R (2022) <http://orthomolecular.org/resources/omns/v18n14.shtml>
9. Ryu J, Sohn I, Do S (2009) Controlled hypotension for middle ear surgery: a comparison between remifentanyl and magnesium sulphate. (中耳手術のための低血圧症管理: レミフェンタニルと硫酸マグネシウムとの比較) British Journal of Anaesthesia 103:490-495. PMID: <https://pubmed.ncbi.nlm.nih.gov/19687032/>
10. Jangra K, Malhotra S, Gupta A, Arora S (2016) Comparison of quality of the surgical field after controlled hypotension using esmolol and magnesium sulfate during endoscopic surgery. (内視鏡手術時にエスモロールと硫酸マグネシウムを用いて低血圧症管理を行った場合の術野の質の比較) Journal of Anaesthesiology, Clinical Pharmacology 32:325-328. PMID: <https://pubmed.ncbi.nlm.nih.gov/27625479/>
11. Juibari H, Eftekharian H Arabion H (2016) Intravenous magnesium sulfate to deliberate hypotension and bleeding after bimaxillary orthognathic surgery; a randomized double-blind controlled trial. (両顎矯正手術後の意図的な低血圧と出血に対する硫酸マグネシウム点滴: 無作為化二重盲検比較試験) Journal of Dentistry 17:276-282. PMID: <https://pubmed.ncbi.nlm.nih.gov/27840841/>
12. Woods K, Fletcher S (1994) Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). (急性心筋梗塞の疑いのある患者における硫酸マグネシウム点滴後の長期転帰: レスターでの第2回マグネシウム点滴介入試験(LIMIT-2)) Lancet 343:816-819. PMID: <https://pubmed.ncbi.nlm.nih.gov/7908076/>

13. Shechter M, Hod H, Rabinowitz B et al. (2003) Long-term outcome of intravenous magnesium therapy in thrombolysis-ineligible acute myocardial infarction patients. (血栓溶解療法には不適合な急性心筋梗塞患者におけるマグネシウム点滴の長期成果) *Cardiology* 99:205-210.
PMID: <https://pubmed.ncbi.nlm.nih.gov/12845247/>
14. Levy T (2019) *Magnesium: Reversing Disease* (疾患を好転させるマグネシウム) Henderson, NV: MedFox Publishing [For a free download of the eBook: <https://mag.medfoxpub.com/>]
15. Huang Y, Lee M, Wahlqvist M (2012) Prediction of all-cause mortality by B group vitamin status in the elderly. (高齢者におけるビタミン B 群の状態による全死因死亡率の予測) *Clinical Nutrition* 31:191-198.
PMID: <https://pubmed.ncbi.nlm.nih.gov/22071291/>
16. Ricci C, Freisling H, Leitzmann M et al. (2020) Diet and sedentary behaviour in relation to cancer survival. A report from the national health and nutrition examination survey linked to the U.S. mortality registry. (ガン生存率に対する食事と座位行動の関連 国民健康栄養調査と米国死亡登録を紐づけた調査報告) *Clinical Nutrition* 39:3489-3496. PMID: <https://pubmed.ncbi.nlm.nih.gov/32229168/>
17. Imdad A, Mayo-Wilson E, Haykal M et al. (2022) Vitamin A supplementation for preventing morbidity and mortality in children from six months to five years of age. (生後 6 カ月～5 歳の子どもの罹患率と死亡率に対するビタミン A 補給の予防効果) *The Cochrane Database of Systematic Reviews* 3:CD008524.
PMID: <https://pubmed.ncbi.nlm.nih.gov/35294044/>
18. Shea M, Barger K, Booth S et al. (2022) Vitamin K status, all-cause mortality, and cardiovascular disease in adults with chronic kidney disease: the Chronic Renal Insufficiency Cohort. (慢性腎臓疾患の成人患者におけるビタミン K の状態、全死因死亡率および循環器疾患: 慢性腎不全コホート) *The American Journal of Clinical Nutrition* 115:941-948. PMID: <https://pubmed.ncbi.nlm.nih.gov/34788785/>
19. Wang J, Fan J, Yang Y et al. (2022) Vitamin D status and risk of all-cause and cause-specific mortality in osteoarthritis patients: results from NHANES III and NHANES 2001-2008. (変形性関節症患者におけるビタミン D の状態、全死因死亡リスクおよび死因別死亡リスク: 2001～2008 年の NHANES III と NHANES から得られた結果) *Nutrients* 14:4629. PMID: <https://pubmed.ncbi.nlm.nih.gov/36364891/>
20. Xu K, Peng R, Zou Y et al. (2022) Vitamin C intake and multiple health outcomes: an umbrella review of systematic reviews and meta-analyses. (ビタミン C 摂取と健康への複数の成果: 体系的レビューとメタ分析の包括的レビュー) *International Journal of Food Sciences and Nutrition* 73:588-599.
PMID: <https://pubmed.ncbi.nlm.nih.gov/35291895/>
21. Hong Y, Zhou Z, Zhang N et al. (2022) Association between plasma vitamin B5 levels and all-cause mortality: a nested case-control study. (血漿中ビタミン B₅ 値と全死因死亡率との関連: ネステッドケースコントロール研究) *Journal of Clinical Hypertension* 24:945-954. PMID: <https://pubmed.ncbi.nlm.nih.gov/35699663/>
22. Liu Y, Geng T, Wan Z et al. (2022) Associations of serum folate and vitamin B12 levels with cardiovascular disease mortality among patients with type 2 diabetes. (2 型糖尿病患者における血清中葉酸・ビタミン B₁₂ 値と循環器疾患死亡率との関連) *JAMA Network Open* 5:e2146124.
PMID: <https://pubmed.ncbi.nlm.nih.gov/35099545/>
23. Xu Q, Qian X, Sun F et al. (2023) Independent and joint associations of dietary antioxidant intake with risk of post-stroke depression and all-cause mortality. (食事での抗酸化物質摂取と、脳卒中後のうつリスクならびに全

死因死亡率との独立的・合同的な関連性) *Journal of Affective Disorders* 322:84-90.

PMID: <https://pubmed.ncbi.nlm.nih.gov/36372128/>

24. Holubiec P, Leonczyk M, Staszewski F et al. (2021) Pathophysiology and clinical management of pellagra-a review. (ペラグラの病態生理と臨床管理 - レビュー) *Folia Medica Cracoviensia* 61:125-137.

PMID: <https://pubmed.ncbi.nlm.nih.gov/34882669/>

25. Fricker R, Green E, Jenkins S, Griffin S (2018) The influence of nicotinamide on health and disease in the central nervous system. (ニコチンアミドが中枢神経系の健康と疾患にもたらす影響) *International Journal of Tryptophan Research* 11:1-11. PMID: <https://pubmed.ncbi.nlm.nih.gov/29844677/>

26. Vignier N, Chatzifrangkeskou M, Rodriguez B et al. (2018) Rescue of biosynthesis of nicotinamide adenine dinucleotide protects the heart in cardiomyopathy caused by lamin A/C gene mutation. (ラミン A/C 遺伝子の突然変異によって生じる心筋症にてニコチンアミドアデニンジヌクレオチドの生合成を回復させることによる心臓の保護効果) *Human Molecular Genetics* 27:3870-3880. PMID: <https://pubmed.ncbi.nlm.nih.gov/30053027/>

27. Bonora M, Patergnani S, Rimessi A et al. (2012) ATP synthesis and storage. (ATP の合成と貯蔵) *Purinergic Signalling* 8:343-357. PMID: <https://pubmed.ncbi.nlm.nih.gov/22528680/>

28. Lopez-Otin C, Blasco M, Partridge L et al. (2013) The hallmarks of aging. (老化の特徴) *Cell* 153:1194-1217. PMID: <https://pubmed.ncbi.nlm.nih.gov/23746838/>

29. Fang E, Lautrup S, Hou Y et al. (2017) NAD⁺ in aging: molecular mechanisms and translational implications. (老化における NAD⁺: 分子機構および翻訳上の影響) *Trends in Molecular Medicine* 23:899-916. PMID: <https://pubmed.ncbi.nlm.nih.gov/28899755/>

30. Imai S, Guarente L (2014) NAD⁺ and sirtuins in aging and disease. (老化と疾患における NAD⁺ とサーチュイン) *Trends in Cell Biology* 24:464-471. PMID: <https://pubmed.ncbi.nlm.nih.gov/24786309/>

31. Yoshino J, Baur J, Imai S (2018) NAD⁺ intermediates: the biology and therapeutic potential of NMN and NR. (NAD⁺ の中間体: NMN と NR のバイオロジーおよび治療可能性) *Cell Metabolism* 27:513-528. PMID: <https://pubmed.ncbi.nlm.nih.gov/29249689/>

32. Mouchiroud L, Houtkooper R, Moullan N et al. (2013) The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. (NAD(+)/サーチュイン経路はミトコンドリアの UPR・FOXO シグナル伝達の活性化により寿命を調整) *Cell* 154:430-441. PMID: <https://pubmed.ncbi.nlm.nih.gov/23870130/>

33. Sohal R, Arnold L, Orr W (1990) Effect of age on superoxide dismutase, catalase, glutathione reductase, inorganic peroxides, TBA-reactive material, GSH/GSSG, NADPH/NADP⁺ and NADH/NAD⁺ in *Drosophila melanogaster*. (キイロショウジョウバエにおける、スーパーオキシドジスムターゼ、カタラーゼ、グルタチオンレダクターゼ、無機過酸化物質、TBA 反応性物質、GSH/GSSG、NADPH/NADP⁺、NADH/NAD⁺に対する齢の影響) *Mechanisms of Ageing and Development* 56:223-235. PMID: <https://pubmed.ncbi.nlm.nih.gov/2128525/>

34. Verdin E (2015) NAD⁺ in aging, metabolism, and neurodegeneration. (老化、代謝、神経変性における NAD⁺) *Science* 350:1208-1213. PMID: <https://pubmed.ncbi.nlm.nih.gov/26785480/>

35. Altschul R, Hoffer A, Stephen J (1955) Influence of nicotinic acid on serum cholesterol in man. (人間の血清中コレステロールに対するニコチン酸の影響) Archives of Biochemistry and Biophysics 54:558-559.
PMID: <https://pubmed.ncbi.nlm.nih.gov/14350806/>
36. Parsons Jr W, Achor R, Berge K et al. (1956) Changes in concentration of blood lipids following prolonged administration of large doses of nicotinic acid to persons with hypercholesterolemia: preliminary observations. (高コレステロール血症患者への長期に及ぶ高用量ニコチン酸投与後の血中脂質濃度の変化: 予備観察) Proceedings of the Staff Meetings (スタッフ会議議事録) Mayo Clinic 31:377-390.
PMID: <https://pubmed.ncbi.nlm.nih.gov/13336128/>
37. Parsons Jr W (2000) Introduction of niacin as the first successful treatment for cholesterol control, a reminiscence. (最初に成功したコレステロール管理療法としてのナイアシンの導入 回顧録) Journal of Orthomolecular Medicine 15:121-126. <http://orthomolecular.org/library/jom/2000/pdf/2000-v15n03-p121.pdf>
38. Ganji S, Kamanna V, Kashyap M (2003) Niacin and cholesterol: role in cardiovascular disease (review). (ナイアシンとコレステロール: 循環器疾患における役割(レビュー)) The Journal of Nutritional Biochemistry 14:298-305. PMID: <https://pubmed.ncbi.nlm.nih.gov/12873710/>
39. Huber R, Wong A (2020) Nicotinamide: an update and review of safety & differences from niacin. (ニコチンアミド: 安全性ならびにナイアシンとの違いに関する最新情報とレビュー) Skin Therapy Letter 25:7-11.
PMID: <https://pubmed.ncbi.nlm.nih.gov/33196157/>
40. Parsons Jr W (2003) Cholesterol Control without Diet! The Niacin Solution. (ダイエットなしでコレステロール管理! ナイアシンという解決策) 2nd ed. Scottsdale, AZ: Lilac Press
41. Filler K, Lyon D, Bennett J et al. (2014) Association of mitochondrial dysfunction and fatigue: a review of the literature. (ミトコンドリア機能不全と疲労との関連: 文献のレビュー) BBA Clinical 1:12-23.
PMID: <https://pubmed.ncbi.nlm.nih.gov/25147756/>
42. Pirinen E, Auranen M, Khan N et al. (2020) Niacin cures systemic NAD⁺ deficiency and improves muscle performance in adult-onset mitochondrial myopathy. (成人発症型ミトコンドリアミオパチーにおいてナイアシンは全身の NAD⁺欠乏の是正と筋パフォーマンスの改善をもたらす) Cell Metabolism 31:1078-1090.
PMID: <https://pubmed.ncbi.nlm.nih.gov/32386566/>
43. Schwemmler J, Maack C, Bertero E (2022) Mitochondria as therapeutic targets in heart failure. (心不全における治療標的としてのミトコンドリア) Current Heart Failure Reports 19:27-37.
PMID: <https://pubmed.ncbi.nlm.nih.gov/35147851/>
44. Starling R, Hammer D, Altschuld (1998) Human myocardial ATP content and in vivo contractile function. (ヒトの心筋の ATP 含有量と生体内収縮機能) Molecular and Cellular Biochemistry 180:171-177.
PMID: <https://pubmed.ncbi.nlm.nih.gov/9546644/>
45. Tannous C, Booz G, Altara R et al. (2021) Nicotinamide adenine dinucleotide: biosynthesis, consumption and therapeutic role in cardiac diseases. (ニコチンアミドアデニンジヌクレオチド: 生合成、消耗、そして心疾患での治療的役割) Acta Physiologica 231:e13551. PMID: <https://pubmed.ncbi.nlm.nih.gov/32853469/>
46. Kalsi K, Smolenski R, Pritchard R et al. (1999) Energetics and function of the failing human heart with dilated or hypertrophic cardiomyopathy. (拡張型または肥大型の心筋症で機能不全に陥ったヒトの心臓のエネ

ルギー特性と機能) European Journal of Clinical Investigation 29:469-477.

PMID: <https://pubmed.ncbi.nlm.nih.gov/10354207/>

47. Diguët N, Trammell S, Tannous C et al. (2018) Nicotinamide riboside preserves cardiac function in a mouse model of dilated cardiomyopathy. (拡張型心筋症のマウスモデルで見られたニコチンアミドリボシドによる心臓機能の維持効果) Circulation 137:2256-2273. PMID: <https://pubmed.ncbi.nlm.nih.gov/29217642/>

48. Abdellatif M, Sedej S, Kroemer G (2021) NAD⁺ metabolism in cardiac health, aging, and disease. (心臓の健康、老化、疾患におけるNAD⁺の代謝) Circulation 144:1795-1817.

PMID: <https://pubmed.ncbi.nlm.nih.gov/34843394/>

49. Trueblood N, Ramasamy R, Wang L, Schaefer S (2000) Niacin protects the isolated heart from ischemia-reperfusion injury. (ナイアシンは単離心臓を虚血再灌流損傷から守る) American Journal of Physiology. Heart and Circulatory Physiology 279:H764-H771. PMID: <https://pubmed.ncbi.nlm.nih.gov/10924076/>

50. Abdellatif M, Trummer-Herbst V, Koser F et al. (2021) Nicotinamide for the treatment of heart failure with preserved ejection fraction. (駆出率が保たれている心不全の治療へのニコチンアミド使用) Science Translational Medicine 13:eabd7064. PMID: <https://pubmed.ncbi.nlm.nih.gov/33568522/>

51. Bays H, Rader D (2009) Does nicotinic acid (niacin) lower blood pressure? (ニコチン酸(ナイアシン)で血圧は下がるか?) International Journal of Clinical Practice 63:151-159.

PMID: <https://pubmed.ncbi.nlm.nih.gov/19054161/>

52. Zhu X, Li J, Wang H et al. (2023) Nicotinamide restores tissue NAD⁺ and improves survival in rodent models of cardiac arrest. (心停止の齧歯類モデルにてニコチンアミドは組織のNAD⁺を回復し生存率を改善) PLoS One 18:e0291598. PMID: <https://pubmed.ncbi.nlm.nih.gov/37713442/>

53. Airhart S, Shireman L, Risler L et al. (2017) An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD⁺ levels in healthy volunteers. (健全なボランティアを被験者としてニコチンアミドリボシド(NR)の栄養サプリメントの薬物動態と血中NAD⁺値への効果を調べた非盲検非無作為化研究) PLoS One 12:e0186459.

PMID: <https://pubmed.ncbi.nlm.nih.gov/29211728/>

54. Hootkooper R, Canto C, Wanders R, Auwerx J (2010) The secret life of NAD⁺: an old metabolite controlling new metabolic signaling pathways. (NAD⁺の知られざる生態: 新しい代謝シグナル伝達経路を制御する古い代謝産物) Endocrine Reviews 31:194-223. PMID: <https://pubmed.ncbi.nlm.nih.gov/20007326/>

55. Canto C, Menzies K, Auwerx J (2015) NAD⁽⁺⁾ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. (NAD⁽⁺⁾の代謝ならびにエネルギー恒常性制御: ミトコンドリアと核とのバランスを保つ作用) Cell Metabolism 22:31-53.

PMID: <https://pubmed.ncbi.nlm.nih.gov/26118927/>

56. Jacobson M, Jacobson E (2018) Vitamin B₃ in health and disease: toward the second century of discovery. (健康と疾患におけるビタミンB₃: 第2の世紀の発見に向けて) Methods in Molecular Biology 1813:3-8.

PMID: <https://pubmed.ncbi.nlm.nih.gov/30097857/>

57. Rotllan N, Camacho M, Tondo M et al. (2018) Therapeutic potential of emerging NAD⁺-increasing strategies for cardiovascular diseases. (新たな NAD⁺増加戦略による循環器疾患治療の可能性) *Antioxidants* 10:1939. PMID: <https://pubmed.ncbi.nlm.nih.gov/34943043/>
58. Mehmel M, Jovanovic N, Spitz U (2020) Nicotinamide riboside-the current state of research and therapeutic uses. (ニコチンアミドリボシド - 研究ならびに治療使用の現状) *Nutrients* 12:1616. PMID: <https://pubmed.ncbi.nlm.nih.gov/32486488/>
59. Sharma C, Donu D, Cen Y (2022) Emerging role of nicotinamide riboside in health and diseases. (健康と疾患におけるニコチンアミドリボシドの新たな役割) *Nutrients* 14:3889. PMID: <https://pubmed.ncbi.nlm.nih.gov/36235542/>
60. Hong G, Zheng D, Zhang L et al. (2018) Administration of nicotinamide riboside prevents oxidative stress and organ injury in sepsis. (敗血症における酸化ストレスと臓器損傷を予ぐニコチンアミドリボシド投与) *Free Radical Biology & Medicine* 123:125-137. PMID: <https://pubmed.ncbi.nlm.nih.gov/29803807/>
61. Poljsak B, Kovac V, Dahmane R et al. (2019) Cancer etiology: a metabolic disease originating from life's major evolutionary transition? (ガンの病因論: 命の大きな進化的変遷に起因する代謝疾患?) *Oxidative Medicine and Cellular Longevity* 2019:7831952. PMID: <https://pubmed.ncbi.nlm.nih.gov/31687086/>
62. Shah G, Shah R, Veillette H et al. (2005) Biochemical assessment of niacin deficiency among carcinoid cancer patients. (カルチノイド腫瘍患者におけるナイアシン欠乏の生化学的評価) *The American Journal of Gastroenterology* 100:2307-2314. PMID: <https://pubmed.ncbi.nlm.nih.gov/16181385/>
63. Kirkland J (2003) Niacin and carcinogenesis. (ナイアシンと発ガン) *Nutrition and Cancer* 46:110-118. PMID: <https://pubmed.ncbi.nlm.nih.gov/14690785/>
64. Chen A, Martin A, Choy B et al. (2015) A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. (皮膚ガンの化学予防に関するニコチンアミドの第3相無作為化試験) *The New England Journal of Medicine* 373:1618-1626. PMID: <https://pubmed.ncbi.nlm.nih.gov/26488693/>
65. Benavente C, Jacobson M, Jacobson E (2009) NAD in skin: therapeutic approaches for niacin. (皮膚中の NAD: ナイアシンの治療的アプローチ) *Current Pharmaceutical Design* 15:29-38. PMID: <https://pubmed.ncbi.nlm.nih.gov/19149600/>
66. Canner P, Berge K, Wenger N et al. (1986) Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. (冠動脈薬プロジェクトの患者における 15 年死亡率: ナイアシンによる長期的効果) *Journal of the American College of Cardiology* 8:1245-1255. PMID: <https://pubmed.ncbi.nlm.nih.gov/3782631/>
67. Liu W, Cao S, Shi D et al. (2023) Association between dietary vitamin intake and mortality in US adults with diabetes: a prospective cohort study. (米国の成人の糖尿病患者における食事でのビタミン摂取量と死亡率との関連: 前向きコホート研究) *Diabetes/Metabolism Research and Reviews* Sep 26. Online ahead of print. PMID: <https://pubmed.ncbi.nlm.nih.gov/37750562/>
68. Langsjoen P, Folkers K, Lyson et al. (1990) Pronounced increase in survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy. (コエンザイム Q10 を従来療法と併用した場合の心筋症患者における生存期間の顕著な延長) *International Journal of Tissue Reactions* 12:163-168. PMID: <https://pubmed.ncbi.nlm.nih.gov/2276894/>

69. Langsjoen P, Langsjoen A (2008) Supplemental ubiquinol in patients with advanced congestive heart failure. (進行したうつ血性心不全患者におけるユビキノール補給) *Biofactors* 32:119-128. PMID: <https://pubmed.ncbi.nlm.nih.gov/19096107/>
70. Oleck S, Ventura H (2016) Coenzyme Q10 and utility in heart failure: just another supplement? (心不全におけるコエンザイム Q10 の効用: ただのサプリメントなのか?) *Current Heart Failure Reports* 13:190-195. PMID: <https://pubmed.ncbi.nlm.nih.gov/27333901/>
71. Lei L, Liu Y (2017) Efficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of clinical trials. (心不全患者におけるコエンザイム Q10 の有効性: 臨床試験のメタ分析) *BMC Cardiovascular Disorders* 17:196. PMID: <https://pubmed.ncbi.nlm.nih.gov/28738783/>
72. Langsjoen P, Langsjoen A, Folkers K (1990) A six-year clinical study of therapy of cardiomyopathy with coenzyme Q10. (コエンザイム Q10 を用いた心筋症療法の 6 年に及ぶ臨床研究) *International Journal of Tissue Reactions* 12:169-171. PMID: <https://pubmed.ncbi.nlm.nih.gov/2276895/>
73. Mortensen S, Rosenfeldt F, Kumar A et al. (2014) The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. (慢性心不全の罹患率と死亡率に対するコエンザイム Q10 の影響: 無作為化二重盲検試験 Q-SYMBIO による結果) *JACC. Heart Failure* 2:641-649. PMID: <https://pubmed.ncbi.nlm.nih.gov/25282031/>
74. Fotino A, Thompson-Paul A, Bazzano L (2013) Effect of coenzyme Q10 supplementation on heart failure: a meta-analysis. (コエンザイム Q10 補給が心不全にもたらす効果: メタ分析) *The American Journal of Clinical Nutrition* 97:268-275. PMID: <https://pubmed.ncbi.nlm.nih.gov/23221577/>
75. Langsjoen P, Langsjoen A, Willis R, Folkers K (1997) Treatment of hypertrophic cardiomyopathy with coenzyme Q10. (コエンザイム Q10 を用いた肥大型心筋症の治療) *Molecular Aspects of Medicine* 18 Suppl:S145-S151. PMID: <https://pubmed.ncbi.nlm.nih.gov/9266516/>
76. Sobirin M, Herry Y, Sofia S et al. (2019) Effects of coenzyme Q10 supplementation on diastolic function in patients with heart failure with preserved ejection fraction. (駆出率が保たれている心不全患者の拡張機能にコエンザイム Q10 補給がもたらす効果) *Drug Discoveries & Therapeutics* 13:38-46. PMID: <https://pubmed.ncbi.nlm.nih.gov/30880321/>
77. Yan H, Zou T, Tuo Q et al. (2021) Ferroptosis: mechanisms and links with diseases. (フェルトーシス: メカニズム、ならびに疾患との関連性) *Signal Transduction and Targeted Therapy* 6:49. PMID: <https://pubmed.ncbi.nlm.nih.gov/33536413/>
78. Walker M, Tian R (2018) Raising NAD in heart failure: time to translate? (心不全において NAD 量を高めること: 翻訳の時?) *Circulation* 137:2274-2277. PMID: <https://pubmed.ncbi.nlm.nih.gov/29784680/>
79. Griffin S, Pickard M, Orme R et al. (2013) Nicotinamide promotes neuronal differentiation of mouse embryonic stem cells in vitro. (ニコチンアミドはマウスの胚性幹細胞の神経分化を促進するという生体内試験の結果) *Neuroreport* 24:1041-1046. PMID: <https://pubmed.ncbi.nlm.nih.gov/24257250/>
80. Griffin S, Pickard M, Orme R et al. (2017) Nicotinamide alone accelerates the conversion of mouse embryonic stem cells into mature neuronal populations. (ニコチンアミドはマウスの胚性幹細胞の成熟ニューロン集団への転換を単独で促進) *PLoS One* 12:e0183358. PMID: <https://pubmed.ncbi.nlm.nih.gov/28817722/>

81. Gasperi V, Sibilano M, Savini I, Catani M (2019) Niacin in the central nervous system: an update of biological aspects and clinical applications. (中枢神経系におけるナイアシン: 生物学的側面と臨床への応用に関する最新情報) *International Journal of Molecular Sciences* 20:974. PMID: <https://pubmed.ncbi.nlm.nih.gov/30813414/>
82. Spector R (1987) Niacinamide transport through the blood-brain barrier. (血液脳関門を通過するナイアシンアミド輸送) *Neurochemical Research* 12:27-31. PMID: <https://pubmed.ncbi.nlm.nih.gov/2952896/>
83. Ito T, Sato T, Takanashi Y et al. (2021) A single oral supplementation of nicotinamide within the daily tolerable upper level increases blood NAD⁺ levels in healthy subjects. (1 日耐容摂取上限内でのニコチンアミド単一経口摂取で健常な被験者における血中 NAD⁺値が上昇) *Translational Medicine of Aging* 5:43-51. <https://www.sciencedirect.com/science/article/pii/S2468501121000055>
84. Cui X, Chopp M, Zacharek A et al. (2010) Niacin treatment of stroke increases synaptic plasticity and axon growth in rats. (ナイアシンを用いた脳卒中治療によりラットのシナプス可塑性と軸索成長が増加) *Stroke* 20671245 <https://pubmed.ncbi.nlm.nih.gov/20671245/>
85. Shehadah A, Chen J, Zacharek A et al. (2010) Niaspan treatment induces neuroprotection after stroke. (ニアスパンを用いた治療は脳卒中後の神経保護作用を誘発) *Neurobiology of Disease* 40:277-283. PMID: <https://pubmed.ncbi.nlm.nih.gov/20554037/>
86. Maiese K, Chong Z (2003) Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. (ニコチンアミド: 必要栄養素が脳の新たな細胞保護物質として浮上) *Trends in Pharmacological Sciences* 24:228-232. PMID: <https://pubmed.ncbi.nlm.nih.gov/12767721/>
87. Mokudai T, Ayoub I, Sakakibara Y et al. (2000) Delayed treatment with nicotinamide (vitamin B₃) improves neurological outcome and reduces infarct volume after transient focal cerebral ischemia in Wistar rats. (ニコチンアミド(ビタミン B₃)を用いた遅延治療はウィスター系ラットにおいて一過性局所脳虚血後の神経学的転帰を改善し梗塞体積を減少) *Stroke* 31:1679-1685. PMID: <https://pubmed.ncbi.nlm.nih.gov/10884473/>
88. Suchard M, Savulescu D (2022) Nicotinamide pathways as the root cause of sepsis-an evolutionary perspective on macrophage energetic shifts. (敗血症の主要因としてのニコチンアミド経路 - マクロファージのエネルギーシフトに関する進化論的視点) *The FEBS Journal* 289:955-964. PMID: <https://pubmed.ncbi.nlm.nih.gov/33686748/>
89. Kujundzic R (2022) COVID-19: are we facing secondary pellagra which cannot simply be cured by vitamin B₃? (COVID-19: ビタミン B₃だけでは治せない続発性ペラグラに我々は直面しているのか?) *International Journal of Molecular Sciences* 23:4309. PMID: <https://pubmed.ncbi.nlm.nih.gov/35457123/>
90. Altay O, Arif M, Li X et al. (2021) Combined metabolic activators accelerates recovery in mild-to-moderate COVID-19. (代謝活性化因子の組合せにより軽度～中等度の COVID-19 の回復を促進) *Advanced Sciences* 8:e2101222. PMID: <https://pubmed.ncbi.nlm.nih.gov/34180141/>
91. Badawy A (2020) Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide. (ポリ(ADP-リボース)ポリメラーゼ阻害物質を用いた COVID-19 の免疫療法: ニコチンアミドから始める) *Bioscience Reports* 40:BSR20202856. PMID: <https://pubmed.ncbi.nlm.nih.gov/33063092/>

92. Raines N, Ganatra S, Nissaisorakarn P et al. (2020) Niacinamide may be associated with improved outcomes in COVID-19-related acute kidney injury: an observational study. (ナイアシンアミドが COVID-19 関連の急性腎臓損傷の転帰改善に関連している可能性: 観察研究) *Kidney360* 2:33-41.
PMID: <https://pubmed.ncbi.nlm.nih.gov/35368823/>
93. Kumakura S, Sato E, Sekimoto A et al. (2021) Nicotinamide attenuates the progression of renal failure in a mouse model of adenine-induced chronic kidney disease. (ニコチンアミドはアデニン誘発性慢性腎臓疾患のマウスモデルにて腎不全の進行を軽減) *Toxins* 13:50. PMID: <https://pubmed.ncbi.nlm.nih.gov/33440677/>
94. Brown O, Heitkamp M, Song C (1981) Niacin reduces paraquat toxicity in rats. (ナイアシンはラットにおいてパラコート毒性を抑制) *Science* 212:1510-1512. PMID: <https://pubmed.ncbi.nlm.nih.gov/7233236/>
95. Hoffer A (1975) Nutrition and schizophrenia. (栄養と統合失調症) *Canadian Family Physician* 21:78-82.
PMID: <https://pubmed.ncbi.nlm.nih.gov/20469184/>
96. Morris M, Schneider J, Tangney C (2006) Thoughts on B-vitamins and dementia. (ビタミン B 群と認知症に関する思索) *Journal of Alzheimer's Disease* 9:429-433. PMID: <https://pubmed.ncbi.nlm.nih.gov/16917152/>
97. Rivadeneira A, Moyer P, Saliccioli J (2019) Pellagra in the USA: unusual manifestations of a rare entity. (米国におけるペラグラ: 稀に実在するものの異常な兆候) *BMJ Case Reports* 12:e230972.
PMID: <https://pubmed.ncbi.nlm.nih.gov/31570356/>
98. Morris M, Evans D, Bienias J et al. (2004) Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline. (食事でのナイアシン摂取と、アルツハイマー病の発症リスクならびに認知機能低下のリスクとの関係) *Journal of Neurology, Neurosurgery, and Psychiatry* 75:1093-1099.
PMID: <https://pubmed.ncbi.nlm.nih.gov/15258207/>
99. Wakade C, Chong R, Bradley E et al. (2014) Upregulation of GPR109A in Parkinson's disease. (パーキンソン病における GPR109A の上方制御) *PLoS One* 9:e109818. PMID: <https://pubmed.ncbi.nlm.nih.gov/25329911/>
100. Hellenbrand W, Boeing H, Robra B et al. (1996) Diet and Parkinson's disease. II. A possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study. (食事とパーキンソン病 II. 過去の特定栄養素摂取について考えられる役割 ケースコントロール研究における自己記入式食事摂取頻度アンケートから得られた結果) *Neurology* 47:644-650.
PMID: <https://pubmed.ncbi.nlm.nih.gov/8797457/>
101. Fall P, Fredrikson M, Axelson O, Granerus A (1999) Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden. (パーキンソン病のリスクに影響する栄養要因と職業的要因: スウェーデン南東部でのケースコントロール研究) *Movement Disorders* 14:28-37.
PMID: <https://pubmed.ncbi.nlm.nih.gov/9918341/>
102. Hoffer L (2008) Vitamin therapy in schizophrenia. (統合失調症におけるビタミン療法) *The Israel Journal of Psychiatry and Related Sciences* 45:3-10. PMID: <https://pubmed.ncbi.nlm.nih.gov/18587164/>
103. Pasternak O, Kubicki M, Shenton M (2016) In vivo imaging of neuroinflammation in schizophrenia. (統合失調症における神経炎症のイメージングの生体内研究) *Schizophrenia Research* 173:200-212.
PMID: <https://pubmed.ncbi.nlm.nih.gov/26048294/>

104. Ansari Z, Pawar S, Seetharaman R (2022) Neuroinflammation and oxidative stress in schizophrenia: are these opportunities for repurposing? (統合失調症における神経炎症と酸化ストレス: 転用の機会なのか?) Postgraduate Medicine 134:187-199. PMID: <https://pubmed.ncbi.nlm.nih.gov/34766870/>
105. Meyer U (2013) Developmental neuroinflammation and schizophrenia. (発達神経炎症と統合失調症) Progress in Neuro-Psychopharmacology & Biological Psychiatry 42:20-34. PMID: <https://pubmed.ncbi.nlm.nih.gov/22122877/>
106. Karlsson H, Dalman C (2020) Epidemiological studies of prenatal and childhood infection and schizophrenia. (出生前および小児期の感染と統合失調症に関する疫学的研究) Current Topics in Behavioral Neurosciences 44:35-47. PMID: <https://pubmed.ncbi.nlm.nih.gov/30852763/>
107. Rund B (2018) The research evidence for schizophrenia as a neurodevelopmental disorder. (神経発達障害としての統合失調症に関する研究エビデンス) Scandinavian Journal of Psychology 59:49-58. PMID: <https://pubmed.ncbi.nlm.nih.gov/29356007/>
108. Falkai P, Schmitt A (2022) Failed regeneration and inflammation in schizophrenia: two sides of the same coin? (統合失調症における再生不全と炎症: 表裏一体?) Journal of Neural Transmission 129:611-615. PMID: <https://pubmed.ncbi.nlm.nih.gov/35451657/>
109. Shah D, Pandey S, Rathi R (1972) Psychiatric manifestations in pellagra. (ペラグラにおける精神医学的兆候) The Journal of the Association of Physicians of India 20:575-578. PMID: <https://pubmed.ncbi.nlm.nih.gov/4680826/>
110. Periyasamy S, John S, Padmavati R et al. (2019) Association of schizophrenia risk with disordered niacin metabolism in an Indian genome-wide association study. (インドでのゲノム規模の関連研究で見られた統合失調症リスクとナイアシン代謝障害との関連性) JAMA Psychiatry 76:1026-1034. PMID: <https://pubmed.ncbi.nlm.nih.gov/31268507/>
111. Prakash R, Gandotra S, Singh L et al. (2008) Rapid resolution of delusional parasitosis in pellagra with niacin augmentation therapy. (ペラグラにおける寄生虫妄想のナイアシン増強療法による迅速な解消) General Hospital Psychiatry 30:581-584. PMID: <https://pubmed.ncbi.nlm.nih.gov/19061687/>
112. Mahler M, Cummings J, Benson D (1987) Treatable dementias. (治療可能な認知症) The Western Journal of Medicine 146:705-712. PMID: <https://pubmed.ncbi.nlm.nih.gov/3617715/>
113. Xu X, Jiang G (2015) Niacin-respondent subset of schizophrenia-a therapeutic review. (統合失調症のナイアシン反応性サブセット - 治療レビュー) European Review for Medical and Pharmacological Sciences 19:988-997. PMID: <https://pubmed.ncbi.nlm.nih.gov/25855923/>
114. Torrey E, Yolken R (2003) Toxoplasma gondii and schizophrenia. (トキソプラズマ原虫と統合失調症) Emerging Infectious Diseases 9:1375-1380. PMID: <https://pubmed.ncbi.nlm.nih.gov/14725265/>
115. Rantala M, Luoto S, Borraz-Leon J, Krams I (2022) Schizophrenia: the new etiological synthesis. (統合失調症: 新たな病因的合成) Neuroscience and Biobehavioral Reviews 142:104894. PMID: <https://pubmed.ncbi.nlm.nih.gov/36181926/>

116. Miklossy J, Khalili K, Gern L et al. (2004) *Borrelia burgdorferi* persists in the brain in chronic Lyme neuroborreliosis and may be associated with Alzheimer's disease. (慢性ライム神経ボレリア症にて脳に存続するボレリア・ブルグドルフェリがアルツハイマー病と関連している可能性) *Journal of Alzheimer's Disease* 6:673-681. PMID: <https://pubmed.ncbi.nlm.nih.gov/15665404/>
117. Sasmita A (2019) Modification of the gut microbiome to combat neurodegeneration. (神経変性に対抗するための腸内微生物叢の改良) *Reviews in the Neurosciences* 30:795-805. PMID: <https://pubmed.ncbi.nlm.nih.gov/31095511/>
118. Wozniak M, Mee A, Itzhaki R (2009) Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques. (アルツハイマー病のアミロイド斑内に単純ヘルペスウイルス 1 型の DNA が存在) *The Journal of Pathology* 217:131-138. PMID: <https://pubmed.ncbi.nlm.nih.gov/18973185/>
119. Alonso R, Pisa D, Marina A et al. (2014) Fungal infection in patients with Alzheimer's disease. (アルツハイマー病患者における真菌感染症) *Journal of Alzheimer's Disease* 41:301-311. PMID: <https://pubmed.ncbi.nlm.nih.gov/24614898/>
120. Dominy S, Lynch C, Ermini F et al. (2019) *Porphyromonas gingivalis* in Alzheimer's disease brains: evidence for disease causation and treatment with small-molecule inhibitors. (アルツハイマー病の脳内のポルフィロモナス・ジンジバリス: 疾患との因果関係ならびに小分子阻害剤を用いた治療に関するエビデンス) *Science Advances* 5:eaau3333. PMID: <https://pubmed.ncbi.nlm.nih.gov/30746447/>
121. Balin B, Gerard H, Arking E et al. (1998) Identification and localization of *Chlamydia pneumoniae* in the Alzheimer's brain. (アルツハイマー病の脳におけるクラミジア・ニューモニエ (クラミジア肺炎病原体) の同定と位置特定) *Medical Microbiology and Immunology* 187:23-42. PMID: <https://pubmed.ncbi.nlm.nih.gov/9749980/>
122. Jiang C, Li G, Huang P et al. (2017) The gut microbiota and Alzheimer's disease. (腸内細菌叢とアルツハイマー病) *Journal of Alzheimer's Disease* 58:1-15. PMID: <https://pubmed.ncbi.nlm.nih.gov/28372330/>
123. Fang X (2016) Potential role of gut microbiota and tissue barriers in Parkinson's disease and amyotrophic lateral sclerosis. (パーキンソン病と筋萎縮性側索硬化症における腸内細菌叢と組織バリアの潜在的役割) *The International Journal of Neuroscience* 126:771-776. PMID: <https://pubmed.ncbi.nlm.nih.gov/26381230/>
124. Ning J, Huang S, Chen S et al. (2022) Investigating casual associations among gut microbiota, metabolites, and neurodegenerative diseases: a Mendelian randomization study. (腸内微生物叢、代謝産物、神経変性疾患における因果関係の調査: メンデルランダム化研究) *Journal of Alzheimer's Disease* 87:211-222. PMID: <https://pubmed.ncbi.nlm.nih.gov/35275534/>
125. Zhuang Z, Yang R, Wang W et al. (2020) Associations between gut microbiota and Alzheimer's disease, major depressive disorder, and schizophrenia. (腸内細菌叢とアルツハイマー病、大うつ病性障害、統合失調症との関連) *Journal of Neuroinflammation* 17:288. PMID: <https://pubmed.ncbi.nlm.nih.gov/33008395/>
126. Picchioni M, Murray R (2007) Schizophrenia. (統合失調症) *BMJ* 335:91-95. PMID: <https://pubmed.ncbi.nlm.nih.gov/17626963/>
127. Madsen A, Keidling N, Karle A et al. (1998) Neuroleptics in progressive structural brain abnormalities in psychiatric illness. (精神疾患における進行性脳構造異常における神経弛緩薬使用) *Lancet* 352:784-785. PMID: <https://pubmed.ncbi.nlm.nih.gov/9737286/>

128. Cahn W, Pol H, Lems E et al. (2002) Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. (統合失調症の初発時における脳体積変化: 1年間の追跡調査) Archives of General Psychiatry 59:1002-1010. PMID: <https://pubmed.ncbi.nlm.nih.gov/12418933/>
129. Emsley R, Asmal L, du Plessis S et al. (2017) Brain volume changes over the first year of treatment in schizophrenia: relationships to antipsychotic treatment. (統合失調症治療の最初の1年間での脳体積変化: 抗精神病薬による治療との関係) Psychological Medicine 47:2187-2196. PMID: <https://pubmed.ncbi.nlm.nih.gov/28347393/>
130. Hirayasu Y (2007) Brain imaging in schizophrenia. (統合失調症における脳撮像) Neuropathology 27:601-603. PMID: <https://pubmed.ncbi.nlm.nih.gov/18021383/>
131. Muller N (2018) Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations. (統合失調症における炎症: 病因的側面および治療での考慮事項) Schizophrenia Bulletin 44:973-982. PMID: <https://pubmed.ncbi.nlm.nih.gov/29648618/>
132. Marques T, Ashok A, Pillinger T et al. (2019) Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies. (統合失調症における神経炎症: 生体内ミクログリア画像研究のメタ分析) Psychological Medicine 49:2186-2196. PMID: <https://pubmed.ncbi.nlm.nih.gov/30355368/>
133. Leng F, Edison P (2021) Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? (アルツハイマー病における神経炎症とミクログリア活性化: 我々はここからどこへ行くのか?) Nature Reviews Neurology 17:157-172. PMID: <https://pubmed.ncbi.nlm.nih.gov/33318676/>
134. Na K, Jung H, Kim Y (2014) The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. (統合失調症の神経炎症とニューロン新生に炎症誘発性サイトカインが果たす役割) Progress in Neuro-Psychopharmacology & Biological Psychiatry 48:277-286. PMID: <https://pubmed.ncbi.nlm.nih.gov/23123365/>
135. Buckley P (2019) Neuroinflammation and schizophrenia. (神経炎症と統合失調症) Current Psychiatry Reports 21:72. PMID: <https://pubmed.ncbi.nlm.nih.gov/31267432/>
136. Murphy C, Walker A, Weickert C (2021) Neuroinflammation in schizophrenia: the role of nuclear factor kappa B. (統合失調症における神経炎症: カップ B 核因子の役割) Translational Psychiatry 11:528. PMID: <https://pubmed.ncbi.nlm.nih.gov/34650030/>
137. Bechter (2013) [Schizophrenia-a mild encephalitis? (統合失調症 - 軽い脳炎?)] ドイツ語の論文 Fortschritte der Neurologie-Psychiatrie 81:250-259. PMID: <https://pubmed.ncbi.nlm.nih.gov/23629631/>
138. Osmond H, Hoffer A (1959) A small research in schizophrenia. (統合失調症についての小規模研究) Canadian Medical Association Journal 80:91-94. PMID: <https://pubmed.ncbi.nlm.nih.gov/13618799/>
139. Lahteenvuo M, Tiihonen J (2021) Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations. (統合失調症の管理を目的とした抗精神病薬の多剤併用: エビデンスおよび推奨事項) Drugs 81:1273-1284. PMID: <https://pubmed.ncbi.nlm.nih.gov/34196945/>
140. Weller M (1987) The spectrum of schizophrenia. (統合失調症のスペクトラム) Postgraduate Medical Journal 63:1021-1024. PMID: <https://pubmed.ncbi.nlm.nih.gov/3330234/>

141. Hoffer A, Osmond H, Callbeck M, Kahan I (1957) Treatment of schizophrenia with nicotinic acid and nicotinamide. (ニコチン酸とニコチンアミドを用いた統合失調症治療) Journal of Clinical and Experimental Psychopathology 18:131-158. PMID: <https://pubmed.ncbi.nlm.nih.gov/13439009/>
142. Sandyk R, Kanofsky J (1993) Vitamin C in the treatment of schizophrenia. (統合失調症治療におけるビタミン C 使用) The International Journal of Neuroscience 68:67-71.
PMID: <https://pubmed.ncbi.nlm.nih.gov/8063516/>
143. Hoffer A, Prousky J (2008) The proper treatment of schizophrenia requires optimal daily doses of vitamin B3. (統合失調症の適切な治療には最適な 1 日用量でのビタミン B₃ 摂取が必要) Journal of Orthomolecular Medicine 23:191-195. <http://orthomolecular.org/library/jom/2008/pdf/2008-v23n04-p191.pdf>
144. Hoffer A, Prousky J (2008) Successful treatment of schizophrenia requires optimal daily doses of vitamin B3. (統合失調症の治療成功には最適な 1 日用量でのビタミン B₃ 摂取が必要) Alternative Medicine Review 13:287-291. PMID: <https://pubmed.ncbi.nlm.nih.gov/19238764/>
145. Hoffer A (1994) Chronic schizophrenic patients treated ten years or more. (治療期間が 10 年以上に及ぶ慢性統合失調症患者) Journal of Orthomolecular Medicine 9:7-37.
146. Hoffer A, Osmond H (1964) Treatment of schizophrenia with nicotinic acid. (ニコチン酸を用いた統合失調症治療) A ten year follow-up. Acta Psychiatrica Scandinavica 40:171-189.
PMID: <https://pubmed.ncbi.nlm.nih.gov/14235254/>
147. Hoffer A (1963) Nicotinic acid: an adjunct in the treatment of schizophrenia. (ニコチン酸: 統合失調症の治療における補助手段) The American Journal of Psychiatry 120:171-173.
PMID: <https://pubmed.ncbi.nlm.nih.gov/13963912/>
148. Osmond H, Hoffer A (1962) Massive niacin treatment in schizophrenia: review of a nine-year study. (統合失調症における大用量ナイアシン治療: 9 年間の研究のレビュー) Lancet 1:316-319.
PMID: <https://pubmed.ncbi.nlm.nih.gov/14482545/>
149. Hoffer A, Saul A, Foster H (2023) Niacin: The Real Story. (ナイアシン: 本当の話) Nashville, TN: Basic Health Publications, Inc.
150. Hoffer A (2020) Light on Schizophrenia: Revealing causes and solutions from an orthomolecular perspective. (統合失調症に関する手掛かり: オートモレキュラー医学の観点から原因と解消法を明らかにする) Victoria, BC: Tellwell Publishing
151. Hoffer A (1971) Megavitamin B-3 therapy for schizophrenia. (統合失調症に対するメガビタミン B-3 療法) Canadian Psychiatric Association Journal 16:499-504. PMID: <https://pubmed.ncbi.nlm.nih.gov/4947171/>
152. Hoffer A (1973) A neurological form of schizophrenia. (統合失調症の神経学的形態) Canadian Medical Association Journal 108:186. PMID: <https://pubmed.ncbi.nlm.nih.gov/4684627/>
153. Premkumar V, Yuvaraj S, Vijayasathy K et al. (2007) Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy. (タモキシフェン療法を受けている乳ガン患者の血清中 CEA 値と CA 15-3 値に対するコエンザイム Q10、リボフラビン、ナイアシンの効果) Biological & Pharmaceutical Bulletin 30:367-370. PMID: <https://pubmed.ncbi.nlm.nih.gov/17268082/>

154. Yuvaraj S, Premkumar V, Vijayasathy K et al. (2008) Augmented antioxidant status in tamoxifen treated postmenopausal women with breast cancer on co-administration with coenzyme Q10, niacin and riboflavin. (タモキシフェン治療を受けていた閉経後の乳ガン女性患者にてコエンザイム Q10、ナイアシン、リボフラビンをを用いた同時投与により抗酸化状態が向上) *Cancer Chemotherapy and Pharmacology* 61:933-941.

PMID: <https://pubmed.ncbi.nlm.nih.gov/17668211/>

155. Premkumar V, Yuvaraj S, Sathish S et al. (2008) Anti-angiogenic potential of Coenzyme Q10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy. (タモキシフェン療法を受けている乳ガン患者にてコエンザイム Q10、リボフラビン、ナイアシンが抗血管新生作用をもたらす可能性) *Vascular Pharmacology* 48:191-201. PMID: <https://pubmed.ncbi.nlm.nih.gov/18407793/>